<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1502210519
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vittoria
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        320,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        83.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vittoria&trade; tablets contain two substances called amlodipine and valsartan.<br />Both of these substances help to control high blood pressure.<br />- Amlodipine belongs to a group of substances called &ldquo;calcium channel<br />blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel<br />wall which stops the blood vessels from tightening.<br />- Valsartan belongs to a group of substances called &ldquo;angiotensin-II<br />receptor antagonists&rdquo;.<br />Angiotensin II is produced by the body and makes the blood vessels<br />tighten, thus increasing the blood pressure. Valsartan works by blocking<br />the effect of angiotensin II.<br />This means that both of these substances help to stop the blood vessels<br />tightening. As a result, the blood vessels relax and blood pressure is<br />lowered.<br />Vittoria&trade; is used to treat high blood pressure in adults whose blood<br />pressure is not controlled enough with either amlodipine or valsartan on<br />its own.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Vittoria&trade;<br />- if you are allergic to amlodipine or to any other calcium channel<br />blockers. This may involve itching, reddening of the skin or difficulty in<br />breathing.<br />- if you are allergic to valsartan or any of the other ingredients of this<br />medicine (listed in section 6). If you think you may be allergic, talk to<br />your doctor before taking Vittoria&trade; .<br />- if you have severe liver problems or bile problems such as biliary<br />cirrhosis or cholestasis.<br />- if you are more than 3 months pregnant. (It is also better to avoid<br />Vittoria&trade; in early pregnancy, see Pregnancy section).<br />- if you have severe low blood pressure (hypotension).<br />- if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic<br />shock (a condition where your heart is unable to supply enough blood to<br />the body).<br />- if you suffer from heart failure after a heart attack.<br />- if you have diabetes or impaired kidney function and you are treated<br />with a blood pressure lowering medicine containing aliskiren.<br />If any of the above applies to you, do not take Vittoria&trade; and talk to<br />your doctor.<br />Warnings and precautions<br />Talk to your doctor before taking Vittoria&trade; :<br />- if you have been sick (vomiting or diarrhoea).<br />- if you have liver or kidney problems.<br />- if you have had a kidney transplant or if you had been told that you have<br />a narrowing of your kidney arteries.<br />- if you have a condition affecting the renal glands called &ldquo;primary<br />hyperaldosteronism&rdquo;.<br />- if you have had heart failure or have experienced a heart attack. Follow<br />your doctor&rsquo;s instructions for the starting dose carefully. Your doctor may<br />also check your kidney function.<br />- if your doctor has told you that you have a narrowing of the valves in<br />your heart (called &ldquo;aortic or mitral stenosis&rdquo;) or that the thickness of your<br />heart muscle is abnormally increased (called &ldquo;obstructive hypertrophic<br />cardiomyopathy&rdquo;).<br />- if you have experienced swelling, particularly of the face and throat,<br />while taking other medicines (including angiotensin converting enzyme<br />inhibitors). If you get these symptoms, stop taking Vittoria&trade; and contact<br />your doctor straight away. You should never take Vittoria&trade; again.<br />- if you are taking any of the following medicines used to treat high blood<br />pressure:<br />&bull; an ACE inhibitor (for example enalapril, lisinopril, ramipril), in<br />particular if you have diabetes-related kidney problems.<br />&bull; aliskiren.<br />Your doctor may check your kidney function, blood pressure, and the<br />amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Vittoria&trade; &rdquo;.<br />If any of these apply to you, tell your doctor before taking<br />Vittoria&trade; .<br />Children and adolescents<br />The use of Vittoria&trade; in children and adolescents is not recommended<br />(aged below 18 years old).<br />Other medicines and Vittoria&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any other medicines. Your doctor may need to change your<br />dose and/or to take other precautions. In some cases you may have to stop<br />taking one of the medicines. This applies especially to the medicines listed<br />below:<br />- ACE inhibitors or aliskiren (see also information under the headings<br />&ldquo;Do not take Vittoria&trade; &rdquo; and &ldquo;Warnings and precautions&rdquo;);<br />- diuretics (a type of medicine also called &ldquo;water tablets&rdquo; which increases<br />the amount of urine you produce);<br />- lithium (a medicine used to treat some types of depression);<br />- potassium-sparing diuretics, potassium supplements, salt substitutes<br />containing potassium and other substances that may increase potassium<br />levels;<br />- certain types of painkillers called non-steroidal anti-inflammatory<br />medicines (NSAIDs) or selective cyclooxygenase-2 inhibitors (COX-2<br />inhibitors). Your doctor may also check your kidney function;<br />- anticonvulsant agents (e.g. carbamazepine, phenobarbital, phenytoin,<br />fosphenytoin, primidone);<br />- St. John&rsquo;s wort;<br />- nitroglycerin and other nitrates, or other substances called<br />&ldquo;vasodilators&rdquo;;<br />- medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);<br />- medicines used to treat fungal infections (e.g. ketoconazole,<br />itraconazole);<br />- medicines used to treat bacterial infections (such as rifampicin,<br />erythromycin, clarithromycin, talithromycin);<br />- verapamil, diltiazem (heart medicines);<br />- simvastatin (a medicine used to control high cholesterol levels);<br />- dantrolene (infusion for severe body temperature abnormalities);<br />- medicines used to protect against transplant rejection (ciclosporin).<br />Vittoria&trade; with food and drink<br />Grapefruit and grapefruit juice should not be consumed by people who are<br />taking Vittoria&trade; . This is because grapefruit and grapefruit juice can lead<br />to an increase in the blood levels of the active substance amlodipine,<br />which can cause an unpredictable increase in the blood pressure lowering<br />effect of Vittoria&trade; .<br />Pregnancy and breast-feeding<br />Pregnancy<br />You must tell your doctor if you think you are (or might become)<br />pregnant. Your doctor will normally advise you to stop taking<br />Vittoria&trade; before you become pregnant or as soon as you know you are<br />pregnant and will advise you to take another medicine instead of Vittoria<br />&trade; . Vittoria&trade; is not recommended in early pregnancy (first 3 months),<br />and must not be taken when more than 3 months pregnant, as it may cause<br />serious harm to your baby if used after the third month of pregnancy.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />Amlodipine has been shown to pass into breast milk in small amounts.<br />Vittoria&trade; is not recommended for mothers who are breast- feeding, and<br />your doctor may choose another treatment for you if you wish to<br />breast-feed, especially if your baby is newborn, or was born prematurely.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />This medicine may make you feel dizzy. This can affect how well you can<br />concentrate. So, if you are not sure how this medicine will affect you, do<br />not drive, use machinery, or do other activities that you need to<br />concentrate on.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor if you are not sure. This will help you get the best results and<br />lower the risk of side effects.<br />The usual dose of Vittoria&trade; is one tablet per day.<br />- It is preferable to take your medicine at the same time each day.<br />- Swallow the tablets with a glass of water.<br />- You can take Vittoria&trade; with or without food. Do not take<br />Vittoria&trade; with grapefruit or grapefruit juice.<br />Depending on how you respond to the treatment, your doctor may suggest<br />a higher or lower dose. Do not exceed the prescribed dose.<br />Vittoria&trade; and older people (age 65 years or over)<br />Your doctor should exercise caution when increasing your dose.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.<br />If you take more Vittoria&trade; than you should<br />If you have taken too many tablets of Vittoria&trade; , or if someone else has<br />taken your tablets, consult a doctor immediately.<br />If you forget to take Vittoria&trade;<br />If you forget to take this medicine, take it as soon as you remember. Then<br />take your next dose at its usual time. However, if it is almost time for your<br />next dose, skip the dose you missed. Do not take a double dose to make up<br />for a forgotten tablet.<br />If you stop taking Vittoria&trade;<br />Stopping your treatment with Vittoria&trade; may cause your disease to get<br />worse. Do not stop taking your medicine unless your doctor tells you to.<br />&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>4. Possible side effects<br />Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Some side effects can be serious and need immediate medical<br />attention:</p><p>A few patients have experienced these serious side effects (may affect up<br />to 1 in 1,000 people).<br />If any of the following happen, tell your doctor straight away:<br />Allergic reaction with symptoms such as rash, itching, swelling of face or<br />lips or tongue, difficulty breathing, low blood pressure (feeling of<br />faintness, light-headedness).<br />Other possible side effects of Vittoria&trade; :<br />Common (may affect up to 1 in 10 people): Influenza (flu); blocked nose,<br />sore throat and discomfort when swallowing; headache; swelling of arms,<br />hands, legs, ankles or feet; tiredness; asthenia (weakness); redness and<br />warm feeling of the face and/or neck.<br />Uncommon (may affect up to 1 in 100 people): Dizziness; nausea and<br />abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands<br />or feet; vertigo; fast heart beat including palpitations; dizziness on<br />standing up; cough; diarrhoea; constipation; skin rash, redness of the skin;<br />joint swelling, back pain; pain in joints.<br />Rare (may affect up to 1 in 1,000 people): Feeling anxious; ringing in the<br />ears (tinnitus); fainting; passing more urine than normal or feeling more of<br />an urge to pass urine; inability to get or maintain an erection; sensation of<br />heaviness; low blood pressure with symptoms such as dizziness, lightheadedness;<br />excessive sweating; skin rash all over your body; itching;<br />muscle spasm.<br />If any of these affect you severely, tell your doctor.<br />Side effects reported with amlodipine or valsartan alone and either<br />not observed with Vittoria&trade; or observed with a higher frequency<br />than with Vittoria&trade; :<br />Amlodipine<br />Consult a doctor immediately if you experience any of the following<br />very rare, severe side effects after taking this medicine:<br />- Sudden wheeziness, chest pain, shortness of breath or difficulty in<br />breathing.<br />- Swelling of eyelids, face or lips.<br />- Swelling of the tongue and throat which causes great difficulty breathing.<br />- Severe skin reactions including intense skin rash, hives, reddening of the<br />skin over your whole body, severe itching, blistering, peeling and swelling<br />of the skin, inflammation of the mucous membranes (Stevens-Johnson<br />Syndrome, toxic epidermal necrolysis) or other allergic reactions.<br />- Heart attack, abnormal heart beat.<br />- Inflamed pancreas, which may cause severe abdominal and back pain<br />accompanied with feeling of being very unwell.<br />The following side effects have been reported. If any of these cause you<br />problems or if they last for more than one week, you should contact your<br />doctor.<br />Common (may affect up to 1 in 10 people):<br />Dizziness, sleepiness; palpitations (awareness of your heart beat);<br />flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea).<br />Uncommon (may affect up to 1 in 100 people):<br />Mood changes, anxiety, depression, sleeplessness, trembling, taste<br />abnormalities, fainting, loss of pain sensation; visual disturbances, visual<br />impairment, ringing in the ears; low blood pressure; sneezing/runny nose<br />caused by inflammation of the lining of the nose (rhinitis); indigestion,<br />vomiting (being sick); hair loss, increased sweating, itchy skin, skin<br />discolouration; disorder in passing urine, increased need to urinate at<br />night, increased number of times of passing urine; inability to obtain an<br />erection, discomfort or enlargement of the breasts in men, pain, feeling<br />unwell, muscle pain, muscle cramps; weight increase or decrease.<br />Rare (may affect up to 1 in 1,000 people): Confusion.<br />Very rare (may affect up to 1 in 10,000 people):<br />Decreased number of white blood cells, decrease in blood platelets which<br />may result in unusual brusing or easy bleeding (red blood cell damage);<br />excess sugar in blood (hyperglycaemia); swelling of the gums, abdominal<br />bloating (gastritis); abnormal liver function, inflammation of the liver<br />(hepatitis), yellowing of the skin (jaundice), liver enzyme increase which<br />may have an effect on some medical tests; increased muscle tension;<br />inflammation of blood vessels often with skin rash, sensitivity to light;<br />disorders combining rigidity, tremor and/or movement disorders.<br />Valsartan<br />Not known (frequency cannot be estimated from the available data):<br />Decrease in red blood cells, fever, sore throat or mouth sores due to<br />infections; spontaneous bleeding or bruising; high level of potassium in<br />the blood; abnormal liver test results; decreased renal functions and<br />severely decreased renal functions; swelling mainly of the face and the<br />throat; muscle pain; rash, purplish-red spots; fever; itching; allergic<br />reaction; blistering skin (sign of a condition called dermatitis bullous).<br />If you experience any of these, tell your doctor straight away.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet. By reporting side effects<br />you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use this medicine after the expiry date which is stated on the carton<br />and blister.<br />Do not store above 30 &deg;C.<br />Store in the original package in order to protect from moisture.<br />Do not use any Vittoria&trade; pack that is damaged or shows signs of<br />tampering.<br />Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Vittoria&trade; contains<br />The active substances of Vittoria&trade; are Amlodipine and valsartan.<br />Vittoria&trade; 5/160mg Film coated Tablets:<br />Each film coated tablet contains 5 mg of Amlodipine as Amlodipine<br />Besylate and 160 mg of Valsartan.<br />Vittoria&trade; 5/320mg Film coated Tablets:<br />Each film coated tablet contains 5 mg of Amlodipine as Amlodipine<br />Besylate and 320 mg of Valsartan.<br />Vittoria&trade; 10/160mg Film coated Tablets:<br />Each film coated tablet contains 10 mg of Amlodipine as Amlodipine<br />Besylate and 160 mg of Valsartan.<br />Vittoria&trade; 10/320mg Film coated Tablets:<br />Each film coated tablet contains 10 mg of Amlodipine as Amlodipine<br />Besylate and 320 mg of Valsartan.<br />Other ingredients are:<br />Vittoria&trade; 5/160mg Film coated Tablets: Microcrystalline cellulose,<br />Crospovidone, Colloidal silicon dioxide, Magnesium stearate,<br />Hypromellose, Titanium dioxide, Iron oxide Yellow, Iron oxide Red,<br />Polyethylene Glycol and Talc.<br />Vittoria&trade; 5/320mg Film coated Tablets: Microcrystalline cellulose,<br />Crospovidone, Colloidal silicon dioxide, Magnesium stearate,<br />Hypromellose, Titanium dioxide, Iron oxide Yellow, Iron oxide Red,<br />Polyethylene Glycol and Talc.<br />Vittoria&trade; 10/160mg Film coated Tablets: Microcrystalline cellulose,<br />Crospovidone, Colloidal silicon dioxide, Magnesium stearate,<br />Hypromellose, Titanium dioxide, Iron oxide Yellow, Polyethylene Glycol,<br />Talc and sunset yellow lake.<br />Vittoria&trade; 10/320mg Film coated Tablets: Microcrystalline cellulose,<br />Crospovidone, Colloidal silicon dioxide, Magnesium stearate,<br />Hypromellose, Titanium dioxide, Iron oxide Yellow, Polyethylene Glycol,<br />Talc and sunset yellow lake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vittoria™ 5/160 mg are Light Yellow colored, Oval, biconvex film
coated tablets debossed with ‘JP’ on one side and ‘58’ on the other side.
Vittoria™ 5/320mg are Light Yellow colored, Oval, biconvex film
coated tablets debossed with ‘JP’ on one side and ‘60’ on the other side.
Vittoria™ 10/160mg are Yellow colored, Oval, biconvex film coated
tablets debossed with ‘JP’ on one side and ‘59’ on other side.
Vittoria™ 10/320mg are Yellow colored, Oval, biconvex film coated
tablets debossed with ‘JP’ on one side and ‘61’ on the other side.
Vittoria™ tablet are available in the following packs:
5/160 mg are available in a box of 4 blisters, 7 tablets per each blister.
5/320mg are available in a box of 4 blisters, 7 tablets per each blister.
10/160mg are available in a box of 4 blisters, 7 tablets per each blister.
10/320mg are available in a box of 4 blisters, 7 tablets per each blister.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فيتوريا&trade; على مادتين فعالتين هما أملوديبين و فالسارتان. تُساعد كلتا المادتين التحكم في ارتفاع ضغط الدَّم.</p><p dir="RTL">- ينتمي أملوديبين إلى مجموعة من الأدوية تسمى &quot;حاصرات قنوات الكالسيوم&quot;. حيث يمنع أملوديبين الكالسيوم من الانتقال إلى جدار الأوعية الدموية مما يمنع تضيق الأوعية الدموية.</p><p dir="RTL">&nbsp;- ينتمي فالسارتان إلى مجموعة من الأدوية تسمى &quot; مضادات مستقبلات الأنجيوتينسين2</p><p dir="RTL">ينتج الجسم أنجيوتينسين ۲ وهو ما يجعل الأوعية الدموية مضغوطة وضيقة مما يؤدي إلى ارتفاع ضغط الدم. يعمل فالسارتان عن طريق منع تأثير انجيوتنسين ۲</p><p dir="RTL">هذا يعني أن كلتا المادتين تساعدان في منع تضيق الأوعية الدموية، مما يؤدي إلى ارتخاء الأوعية الدَّموية وخفض ضغط الدَّم.</p><p dir="RTL">لعلاج ارتفاع ضغط الدم في المرضى من البالغين الذين لا يمكن التحكم بشكل &trade; يُستخدم فيتوريا</p><p dir="RTL">كافِ في ضغط الدم لديهم من خلال استخدام أملوديبين أو فالسارتان كل على حدة. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>في الحالات التالیة: &trade; لا تتناول فيتوريا</p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه أملوديبين أو إلى أي من حاصرات قنوات الكالسيوم الأخرى. قد يشمل ذلك حدوث حكة أو احمرار الجلد أو صعوبة في التنفس.</p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه فالسارتان أو تجاه أي مكون من المكونات الأخرى الداخلة بتركيب هذا الدَّواء (المدرجة في قسم رقم ٦). إذا كنت تعتقد بأنك قد تكون مصابًا بحساسية، تحدث &nbsp;إلى طبيبك قبل تناول فيتوريا&trade;.</p><p dir="RTL">- إذا كنت تعاني من مشاكل شديدة بالكبد أو مشاكل في العصارة الصفراوية مثل تليف الكبد الصفراوي أو ركود صفراوي.</p><p>- إذا كان حملكِ قد تجاوز الشهر الثالث. (من الأفضل أيضًا تجنُّب تناوُل فيتوريا&trade; في مراحل الحمل المُبكرة، انظريِ قسم &quot;الحمل&quot;).</p><p dir="RTL">- إذا كنت تٌعاني من انخفاض حاد في ضغط الدم (انخفاض ضغط الدم).</p><p>- إذا كنت تٌعاني من ضيق في صمام القلب الأبهري (تضيق الأبهر) أو صدمة قلبية (هي حالة يكون فيها القلب غير قادر على إمداد الجسم بقدر كاف من الدم)</p><p dir="RTL">- إذا كنت تُعاني من فشل القلب بعد الإصابة بأزمة قلبية.</p><p dir="RTL">- إذا كنت مصابًا بداء السُّكَّري أو تُعاني من قصور وظائف الكُلى، وتخضع لعلاج بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.</p><p><strong>لا تتناول فيتوريا&trade; إذا انطبقت عليك أيٌّ حالة من الحالات المذكورة أعلاه واستشر طبيبك.</strong><br /><strong>تحذيرات واحتياطات</strong><br />تحدث إلى طبيبك قبل تناول فيتوريا&trade; في الحالات الآتية:</p><p dir="RTL">- إذا كنت تعاني من إعياء (قيء أو إسهال).</p><p dir="RTL">- إذا كنت تعاني من مشاكل بالكبد أو الكلى.</p><p dir="RTL">- إذا كنت قد خضعت لعملية زرع كلى أو إذا تم إخبارك بأنك تعاني من ضيق في شرايين الكلى.</p><p dir="RTL">- إذا كنت تعاني من حالة مرضية تؤثر على الغدد الكلوية تسمى فرط الألدوستيرونية الأولية &quot;هي</p><p dir="RTL">حالة مرضية تتصف بزيادة إنتاج ألدوستيرون من الغدد الكظرية مما يتسبب في انخفاض مستوى البوتاسيوم في الدم&quot;.</p><p dir="RTL">- إذا كنت تُعاني من فشل القلب أو تعرضت لأزمة قلبية. اتبع بعناية تعليمات طبيبك بشأن جُرعة البدء. كما قد يفحص طبيبك وظائف الكُلى لديك.</p><p dir="RTL">- إذا أخبرك طبيبك أنك تعاني من ضيق في صمامات القلب (حالة تسمى &quot;تَضَيُّقُ تاجي أو اَبْهَرِيّ&quot;) أو قد يتضخم سُمك عضلة القلب بشكل غير طبيعي (يُسمى &quot;اعتلال عضلة القلب الضخامي الانسدادي&quot;).</p><p dir="RTL">- إذا كنت تعاني من تورم على وجه الخصوص في الوجه والحلق أثناء تناول أدوية أخرى (بما في</p><p dir="RTL">إذا أُصِبت بأي من هذه ذلك مثبطات الإنزيم المحول للأنجيوتنسين). توقَّف عن تناوُل فيتوريا&trade;</p><p dir="RTL">مرة أخرى. الأعراض واتصل بطبيبك فورًا. ويحظر تتناول فيتوريا&trade;</p><p dir="RTL">- إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:</p><p dir="RTL">&bull; مثبط الإنزيم المُحَوِّل للأنجيوتنسين (مثل: إنالابريل، ليزينوبريل، راميبريل) وعلى وجه</p><p dir="RTL">الخصوص إذا كنت تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكَّري.</p><p dir="RTL">&bull; أليسكيرين.</p><p dir="RTL">قد يُجري طبيبك بانتظام فحصًا لوظائف الكُلى وضغط الدَّم وكمية الكهارل (مثل: البوتاسيوم) في</p><p dir="RTL">الدم.</p><p dir="RTL">انظر أيضًا المعلومات تحت عنوان: &quot;لا تتناول فيتوريا&quot;&trade;<br /><strong>&trade; </strong><strong>أبلغ طبيبك قبل تناول فيتوريا&trade; إذا انطبقت عليك أيٌّ حالة من الحالات السابقة</strong><strong>. </strong><br /><strong>المرضى من الأطفال والمراهقين</strong><br />لا يُوصى باستخدام فيتوريا&quot;&trade; في المرضى من الأطفال والمراهقين (الذين تقل أعمارهم عن 18 عام</p><p>اسم وعنوان مالك رخصة التسويق و المصنع</p><p>تناول فيتوريا&trade; مع أدوية أخرى<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. قد يحتاج<br />طبيبك إلى تغير الجرعة الخاصة بك و/أو اتخاذ احتيطات أخرى. قد تكون مضطرًا في بعض<br />الحالات للتَّوقف عن تناوُل أحد الأدوبة. ينطبق هذا بشكل خاص على الأدوية المُدرَجة أدناه:<br />- مثبطات الإنزيم المحول للأنجيوتنسين أو أليسكيرين(انظر أيضًا المعلومات الواردة تحت العناوين لا تتناول لا تتناول&nbsp;فيتوريا&trade; &quot;تحذيرات واحتياطات&quot;)<br />- مدرات البول (نوع من الأدوية تسمى أيضاً &quot;أقراص الماء&quot; وتزيد من إدرار البول).<br />- اللليثوم (دواء يستخدم لعلاج بعض أنواع الاكتئاب)<br />- أدوية إدرار البول الموفرة للبوتاسيوم، مكملات البوتاسيوم، بدائل الملح التي تحتوي على<br />البوتاسيوم ومواد أخرى قد ترفع مستويتت البوتاسيوم؛<br />- أنواع مُعينة من مُسكِّنات الألم تُسمى مُضادات الالتهاب غير الستيرويدية (NSAIDs)أو&nbsp; مثبطات إنزيمات الأكسدة الحلقية الانتقائية (مثبطات COX-2)<br />كما قد يفحص طبيبك وظائف الكُلى لديك؛<br />- أدوية مضادة للصرع (مثل كاربامازبين، فينوباربيتال ، فينيتوين، فوسفنيتوين، بريميدون)<br />- نبتة سانت جونز؛<br />- نتروجلسرين والنترات الأخرى أو المواد الأخرى التي تسمى &quot;موسعات الأوعية&quot;؛<br />- الأدوية التي تستخدم لعلاج فيروس نقص المناعة البشري/أو متلازمة نقص المناعة المكتسبة<br />(الإدوية) (على سبيل المثال؛ ريتونافير، إندينافير، نلفينافير)<br />- الأدوية التي تستخدم لعلاج الالتهابات الفطرية (على سبيل المثال؛ كيتوكونازول،<br />إيتراكونازول).<br />- الأدوية التي تستخدم لعلاج الالتهابات البكتيرية (مثل ريفامبيسين، إريثروميسين،<br />كلاريثرين، تيليثرومسين)؛<br />- فيراباميل و ديلتيازيم (أدوية تستخدم لعلاج أمراض القلب)<br />- سيمفاستاتين (دواء يستخدم للتحكم في ارتفاع مستويات الكوليسترول<u>)</u><br />- دانترولين (دواء للحقن التسريبيي يستخدم لعلاج اضطرابات درجة حرارة الجسم الشديدة)<br />- الأدوية التي تستخدم لحماية الجسم من رفض الأعضاء المزروعة (سيكلوسبورين)<br />تتناول&nbsp;فیتوریا&trade; مع الطعام والمشروبات<br />يُحظر علآ المرضى الذين يناولون فیتوریا &trade; شرب عصير الجريب فروت أو تناول الجريب فروز وذلك لأن الجريب فروت و عصير الجريب فروت يمكن أن يؤدي إلى زيادة المادة الفعالة أملوديبين في مستويات الدم ما قد يسبب زيادة غير متوقعة في تأثير انخفاض ضغط الدم نتيجة لتناول فيتوريا&trade; &nbsp;</p><p>الحمل والرضاعة الطبيعية<br />الحمل</p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حاملاً (أو قد تصبحين) حاملًا. سينصحكِ طبيبك</p><p dir="RTL">قبل أن تصبحي حاملاً أو بمجرد أن تعلمي أنكِ حامل &nbsp;عادةً بالتوقف عن تناول فيتوريا&trade;</p><p dir="RTL">أثناء الفترة &nbsp;لا يوصى باستخدام فيتوريا .&trade; وسينصحكِ بتناول عقار آخر بدلًا من فيتوريا&trade;</p><p dir="RTL">الأولى من الحمل (الأشهر الثلاثة الأولى من الحمل). يُحظر عليك تناول هذا العقار إذا تجاوز</p><p dir="RTL">حملكِ الشهر الثالث حيث إنه قد يُسبب أضرارًا خطيرة لطفلكِ إذا تم تناوله بعد الشهر الثالث من</p><p dir="RTL">الحمل.</p><p><br />الرَّضاعة الطبيعية</p><p dir="RTL">أخبري طبيبكِ إذا كنتِ تُمارسين الرَّضاعة الطبيعية، أو على وشك البدء في الرَّضاعة الطبيعية.</p><p dir="RTL">أثبتت الدراسات أن أملوديبين يفرز في لبن الأم بكميات ضئيلة. ولا يوصي المرضى من الأمهات</p><p dir="RTL">وقد يقرر طبيبك علاجًا آخر إذا كنتِ &nbsp;اللواتي يمارسن الرضاعة الطبيعية بتناول فيتوريا&trade;</p><p dir="RTL">ترغبين في ممارسة الرضاعة الطبيعية ولا سيمًا إذا كان طفلكِ حديث الولادة أو ولد مبكرًا.</p><p dir="RTL">استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">.<br />القيادة واستخدام الآلات<br />قد يسبب لك هذا الدواء شعورًا بالدوخة، مما قد يؤثر على مدى التركيز لديك. لذا، إذا لم تكن<br />متأكدًا من تأثير هذا الدواء عليك فلا تقم بقيادة السيارة أو استخدام الآلات أو القيام بأية أنشطة<br />أخرى تحتاج إلى تركيز</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء تمامًا كما أخبرك طبيبك. يُرجى مراجعة طبيبك إذا لم تكن متأكدًا من كيفية</p><p dir="RTL">التناول. سيساعدك هذا على الحصول على أفضل النتائج وسيقلل من خطورة الآثار الجانبية.</p><p dir="RTL">هي قرص واحد يوميًا. الجرعة المعتادة منفيتوريا&trade;</p><p dir="RTL">- يفضل تناول العقار في نفس الوقت من كل يوم.</p><p dir="RTL">- ابتلع الأقراص مع كوب من الماء.</p><p dir="RTL">- يمكنك تناول فيتوريا&trade; مع الطعام أو بدونه</p><p dir="RTL">. لا تتناول فيتوريا&trade; مع الجريب فروت أو عصير الجريب فروت &nbsp;.</p><p dir="RTL">قد يصف طبيبك جرعة أعلى أو أقل وذلك حسب استجابتك للعلاج. لا تتجاوز تناول الجرعات</p><p>التي تم وصفها لك.</p><p dir="RTL"><strong>في المرضى من كبار السن (البالغين من العمر ٦٥ عامًا أو أكثر) تناول فيتوريا&trade;</strong></p><p dir="RTL">يجب على طبيبك توخي الحذر عند زيادة الجرعة.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي.</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من</strong> <strong>فيتوريا&trade;</strong></p><p dir="RTL">أو إذا تناول أي شخص &nbsp;قم باستشارة طبيبك فورًا إذا تناولت كمية أكثر مما يجب من <strong>فالسابين&trade;</strong></p><p dir="RTL">آخر بعض الأقراص الخاصة بك.</p><p dir="RTL"><strong>&trade;<strong> </strong>إذا أغفلت تناول فيتوريا</strong></p><p dir="RTL">إذا أغفلت تناول الجرعة الخاصة بك من هذا العقار فتناولها بمُجرد تذكُّرك لها. بعد ذلك، تناول</p><p dir="RTL">جرعتك التالية في وقتها المعتاد. ومع ذلك، إذا كان قد حان موعد الجُرعة التَّالية فتجاوَز الجُرعة</p><p dir="RTL">التي أغفلتها. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>&trade; إذا توقفتِ عن تناول فيتوريا</strong></p><p dir="RTL">إلى تفاقُم حدة المرض الذي تعاني منه. فلا تتوقَّف عن تناوُل هذا &nbsp;قد يُؤدي إيقاف تناول <strong>فالسابين</strong>&trade;</p><p dir="RTL">الدَّواء ما لم يُخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبب هذا الدواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لدى جميع</p><p dir="RTL">المرضى.</p><p dir="RTL"><strong>يمكن أن تكون بعض الآثار الجانبية خطيرة وقد تحتاج إلى عناية طبية عاجلة</strong><strong>:</strong></p><p dir="RTL">قد عانى القليل من المرضى من هذه الآثار الجانبية الخطيرة (قد تُؤثر فيما يصل إلى مريض واحد</p><p dir="RTL">من بين كل ۱۰۰۰ مريض(</p><p dir="RTL"><strong>أخبر طبيبك فورًا إذا حدث لك أيٌّ مما يلي</strong><strong>:</strong></p><p dir="RTL">تفاعل تحسسي مصاحب لأعراض مثل طفح جلدي، حكة، تورم في الوجه أو الشفتين أو اللسان،</p><p dir="RTL">صعوبة في التنفس، انخفاض ضغط الدم (إغماء، شعور بخفة الرأس)</p><p><strong>الآثار الجانبية الأخرى المحتملة لفيتوريا</strong></p><p><strong>آثار جانبية شائعة </strong>(قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى):</p><p>إنفلونزا، انسداد الأنف، التهاب الحلق، صعوبة عند البلع، صداع، تَّورم الذراعين واليدين والأرجل</p><p dir="RTL">والكاحلين أو القدمين، إرهاق، وهن (ضعف)، احمرار وحرارة في الوجه و /أو الرقبة.</p><p><strong>آثار جانبية غير شائعة</strong> (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰ مريض):<br />دوخة، غثيان، ألم بالبطن، جفاف الفم، نعاس، وخز أو خدر في اليدين أو القدمين، دوار، سرعة<br />ضربات القلب بما في ذلك خفقان، دوخة عند الوقوف، سعال، إسهال، إمساك، طفح جلدي،<br />احمرار في الجلد، تورم المفاصل، ألم بالظهر وألم في المفاصل.</p><p><br /><strong>آثار جانبية نادرة</strong> (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰۰ مريض):<br />شعور بالقلق، رنين في الأذنين (طنين)، إغماء، تبول أكثر من المعتاد أو الشعور بكثرة الحاجة<br />إلى التبول، عدم القدرة على تحقيق أو الحفاظ على الانتصاب، إحساس بالثقل، انخفاض ضغط<br />الدم المصحوب بأعراض مثل دوخة، دوار، فرط التعرق، طفح جلدي منتشر في جميع أجزاء<br />الجسم، حكة، تشنج بالعضلات.<br />أخبر طبيبك، إذا أصبت بأي من هذه الآثار الجانبية بدرجة شديدة.<br />تم الإبلاغ عن آثار جانبية مع تناول أملوديبين و فالسارتان بشكل منفرد ولم يتم ملاحظتها مع تناول فيتوريا<strong>&trade;</strong><br />تم الإبلاغ عن اثار جانبية مع تناول أملوديبين و فالسارتين بشكل منفرد و لم يتم ملاحظتها مع تناول فيتوريا &trade;</p><p>أو تم ملاحظة حدوثها بمعدل تكرار أعلى من معدل حدوثها عند تناول فيتوريا&trade;<br />استشر طبيبك فورًا إذا كنت تعاني من الآثار جانبية التالية:<br />آثار جانبية نادرة جدًا، وآثار جانبية شديدة بعد تناول هذا الدواء:<br />- أزيز مفاجئ، ألم بالصدر أو ضيق النفس أو صعوبة في التنفس.<br />- تورم الجفون أو الوجه أو الشفتين.<br />- تورم اللسان والحلق مما قد یُسبب صعوبة كبيرة في التنفس.<br />- تفاعلات جلدية شديدة تشمل طفح جلدي شديد، شرى، احمرار جلد الجسم كله، حكة شدیدة،<br />تقرحات وتقشر وتورم في الجلد والتهاب الأغشية المخاطية (متلازمة ستيفنز جونسون، تَقَشُّرُ<br />الأَنْسِجَةِ المُتَمَوِّتَةِ البشروية التَّسممي) وتفاعلات حساسية أخرى.<br />- نوبة قلبية واضطرابات في ضربات (نظم) القلب.<br />- التهاب البنكرياس مما قد يسبب ألم البطن وألم الظهر الذي يصاحبه شعور بالإعياء الشديد.<br />تم الإبلاغ عن الآثار الجانبية التالية. يجب عليك الاتصال بطبيبك إذا تسببت هذه الآثار في<br />حدوث مشاكل لك أو إذا استمرت لأكثر من أسبوع واحد.<br />آثار جانبية شائعة: (قد تُؤثر فيما يصل إلى مريض واحد من بين كل ۱۰ مرضى):<br />دوخة، نعاس، خَفَقان القلْب (شعور بنبضات قلبك) احمرار الجلد، تورم الكاحل (وذمة)، ألم في<br />البطن، وشعور بالإعياء (الغثيان).<br />آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰ مريض):<br />تغيرات في المزاج، قلق، اكتئاب، أرق، ارتجاف، مذاق غير طبيعي، إغماء، فقدان الإحساس<br />بالألم، اضطرابات بصرية، قصور البصر، صفير في الأذنين انخفاض ضغط الدَّم، عطس<br />/سيلان الأنف الناجم عن التهاب بطانة الأنف (التهاب الأنف)، عسر هضم، قيء (شعور<br />بالإعياء)، تساقط الشعر، زيادة التعرُّق، حكة بالجلد، تغير لون الجلد، اضطراب في التبول،<br />زيادة الحاجة إلى التبول أثناء الليل وزيادة عدد مرات التبول، عدم القدرة على تحقيق الانتصاب،<br />شعور بعدم الراحة أو زيادة حجم الثدي لدى الرجال، ألم، وشعور بأنك لست على ما يرام، ألم<br />عضلي، تشنجات عضلية وزيادة أو نقصان الوزن.<br />آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰۰ مريض): ارتباك<br />آثار جانبية نادرة جدًا (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰,۰۰۰ مريض):<br />انخفاض عدد خلايا الدم البيضاء، نقص في الصفائح الدموية مما قد يؤدي إلى كدمات غير عادية<br />أو سهولة حدوث نزيف (تلف خلايا الدم الحمراء) ، زيادة سكر الدم (فرط سكر الدم)، تورم<br />اللثة، انتفاخ البطن (التهاب المعدة)، (التهاب الكبد)، اصفرار الجلد (يرقان)، زيادة إنزيم الكبد<br />مما يأثر على نتائج بعض الفحوصات الطبيعة، زيادة الشد العضلي، التهاب الأوعية الدموية<br />المصحوب غالبًا بطفح جلدي، حساسية تجاه الضوء، الاضطرابات المصاحبة للتيبس، ارتعاش،<br />و/أو اضطرابات في الحركة.<br />فالسارتان<br /><strong>آثار جانبية غير معروف معدل تكرارها </strong>(لا يمكن تقدير معّدل التكرار من واقع البيانات المتاحة):<br />انخفاض خلايا الدم الحمراء، حمى، التهاب الحلق أو تقرحات الفم بسبب حدوث عدوى، نزيف<br />تلقائي أو كدمات، ارتفاع مستوى البوتاسيوم في الدم، نتائج غير طبيعية لفحص وظائف الكبد،<br />انخفاض وظائف الكلى، انخفاض حاد بوظائف الكلى، تورم الوجه والحلق، ألم عضلي، طفح<br />جلدي، بقع حمراء أرجوانية، حمى، حكة، رد فعل تحسسي، وتقرح الجلد (علامة على وجود<br />حالة تسمى التهاب الجلد الفقاعي).<br />إذا عانيت من أيٍّ من هذه الآثار الجانبية، أخبر طبيبك على الفور.<br />الإبلاغ عن الآثار الجانبية<br />إذا أصبت بأية آثار جانبية، تحدَّث إلى طبيبك أو الصيدلي ويشمل ذلك أية آثار جانبية مُحتمَلة<br />غير مُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية يمكنك المساعدة في توفير<br />معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول و مرأى الأطفال.<br />لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />يحفظ في العبوة الأصلية وذلك لحمايتها من الرطوبة.<br />.&trade; لا تستخدم أي عبوة تالفة أو تظهر عليها علامات عبث من فيتوريا&trade;<br />لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو المخلفات المنزلية. استشر الصيدلي<br />حول كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على<br />البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا يحتوي فيتوريا&trade;</p><p>المواد الفعالة في فيتوريا&trade; هي ملوديبين و فالسارتان.</p><p>فيتوريا&nbsp;&trade;٥ /۱٦۰ ملجم أقراص مغلفة:&nbsp;<br />يحتوي كل قرص مغلف على ٥ ملجم من أملودبين على هيئة أملوديبين بسيليت و ۱٦۰ ملجم من<br />فالسارتان.<br />فيتوريا&nbsp;&trade;٥ /۳۲۰ ملجم أقراص مغلفة:&nbsp;<br />يحتوي كل قرص مغلف على ٥ ملجم من أملودبين في شكل أملوديبين بسيليت ، و ۳۲۰ ملجم من<br />فالسارتان.<br />فيتوريا۱۰&nbsp; /&nbsp;۱٦۰ ملجم أقراص مغلفة:<br />يحتوي كل قرص مغلف على ۱۰ ملجم من أملوديبين على هيئة أملوديبين بسيليت و ۱٦۰ ملجم<br />من فالسارتان.<br />فيتوريا&nbsp;&trade; ۱۰ /۳۲۰ ملجم أقراص مغلفة:<br />يحتوي كل قرص مغلف على ۱۰ ملجم من أملوديبين على هيئة أملوديبين بسيليت و ۳۲۰ ملجم<br />من فالسارتان.<br />المكونات الأخرى ھي:</p><p>فيتوريا<strong>&nbsp;&trade;٥ /۱٦۰ ملجم: </strong></p><p>سليلوز دقيق التبلور، كروسبوفيدون، ثاني أكسيد السليكون<strong>&trade;</strong>فيتوريا</p><p>الغروي، ستيرات الماغنسيوم، هيبروميلوز ، ثاني أكسيد التيتانيوم ، أكسيد الحديد الأصفر ،</p><p>أكسيد الحديد الأحمر ، بولي إيثيلين جليكول و تلك.</p><p>فيتوريا<strong>&trade;٥ /۳۲۰ ملجم </strong><br />سليلوز دقيق التبلور، كروسبوفيدون، ثاني أكسيد السليكون<br />الغروي، ستيرات الماغنسيوم، هيبروميلوز ، ثاني أكسيد التيتانيوم ، أكسيد الحديد الأصفر ،<br />أكسيد الحديد الأحمر ، بولي إيثيلين جليكول و تلك.</p><p>فيتوريا<strong> ۱۰&nbsp; /&nbsp;۱٦۰ ملجم أقراص مغلفة: </strong></p><p>سليلوز دقيق التبلور، كروسبوفيدون، ثاني أكسيد السليكون<br />الغروي، ستيرات الماغنسيوم، هيبروميلوز ، ثاني أكسيد التيتانيوم ، أكسيد الحديد الأصفر ،<br />بولي إيثيلين جليكول و تلك و لون الغروب الأصفر.<br />فيتوريا<strong>&nbsp;&trade; ۱۰ /۳۲۰ ملجم أقراص مغلفة: </strong></p><p>سليلوز دقيق التبلور، كروسبوفيدون، ثاني أكسيد السليكون<br />الغروي، ستيرات الماغنسيوم، هيبروميلوز ، ثاني أكسيد التيتانيوم ، أكسيد الحديد الأصفر ،<br />&nbsp;، بولي إيثيلين جليكول و تلك. لون الغروب الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">فيتوريا<strong>&nbsp;&trade;٥ /۱٦۰ ملجم: </strong></p><p style="text-align:right">أقراص مغلفة ثنائية التحدُّب، بيضاوية الشكل، لونها أصفر فاتح، محفور على أحد جانبيها &quot;JP&quot; &nbsp; وعلى الجانب الآخر &quot; 58</p><p style="text-align:right">فيتوريا<strong>&nbsp;&trade;٥ /۳۲۰ ملجم </strong><br />أقراص مغلفة ثنائية التحدُّب، بيضاوية الشكل، لونها أصفر فاتح، محفور على أحد جانبيها &quot;JP&quot; &nbsp; وعلى الجانب الآخر &quot; 60</p><p style="text-align:right">فيتوريا<strong>۱۰&nbsp; /&nbsp;۱٦۰ ملجم أقراص مغلفة: </strong></p><p style="text-align:right">أقراص مغلفة ثنائية التحدُّب، بيضاوية الشكل، لونها أصفر، محفور على أحد جانبيها&nbsp;&quot;JP&quot; وعلى الجانب الآخر &quot;&nbsp; 59<br />فيتوريا<strong>&nbsp;&trade; ۱۰ /۳۲۰ ملجم أقراص مغلفة: </strong></p><p style="text-align:right">أقراص مغلفة ثنائية التحدُّب، بيضاوية الشكل، لونها أصفر&nbsp; محفور على أحد جانبيها &quot;JP&quot; &nbsp; وعلى الجانب الآخر &quot; 61</p><p style="text-align:right">&nbsp; تتوفر أقراص فيتوريا<strong>&nbsp;&trade;</strong>في العبوات التالية:<br />٥ /۱٦۰&nbsp; ملجم: علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص .<br />٥ /۳۲۰ &nbsp;ملجم: علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص.<br />۱۰&nbsp; /&nbsp;۱٦۰ ملجم: علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص<br />۱۰ /۳۲۰ ملجم: علبة تحتوي على ٤ شرائط في كل شریط ۷ أقراص.<br />قد لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>&nbsp;هاتف: 6081111-12-966+</p><p>&nbsp;فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني www.jamjoompharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vittoria 10/320 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate) and 320 mg of
valsartan.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />Amlodipine/Valsartan tablets are indicated in adults whose blood pressure is not adequately controlled<br />on amlodipine or valsartan monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The recommended dose of Amlodipine/Valsartan tablets is one tablet per day.<br />Amlodipine/Valsartan tablets may be administered in patients whose blood pressure is not adequately<br />controlled with amlodipine 5 mg or valsartan 160 mg alone.<br />Amlodipine/Valsartan tablets may be administered in patients whose blood pressure is not adequately<br />controlled with amlodipine 10 mg or valsartan 160 mg alone.<br />Amlodipine/Valsartan tablets may be administered in patients whose blood pressure is not adequately<br />controlled with amlodipine 5 mg or valsartan 320 mg alone.<br />Amlodipine/Valsartan tablets may be administered in patients whose blood pressure is not adequately<br />controlled with amlodipine 10 mg or valsartan 320 mg alone.<br />Amlodipine/Valsartan tablets can be used with or without food.<br />Individual dose titration with the components (i.e. amlodipine and valsartan) is recommended before<br />changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy<br />to the fixed-dose combination may be considered.<br />For convenience, patients receiving valsartan and amlodipine from separate tablets/capsules may be<br />switched to Amlodipine/Valsartan tablets containing the same component doses.<br />Renal impairment<br />There are no available clinical data in severely renally impaired patients. No dosage adjustment is<br />required for patients with mild to moderate renal impairment. Monitoring of potassium levels and<br />creatinine is advised in moderate renal impairment.<br />Hepatic impairment<br />Amlodipine/Valsartan tablets is contraindicated in patients with severe hepatic impairment (see section<br />4.3).<br />Caution should be exercised when administering Amlodipine/Valsartan tablets to patients with hepatic<br />impairment or biliary obstructive disorders (see section 4.4). In patients with mild to moderate hepatic<br />impairment without cholestasis, the maximum recommended dose is 80 mg valsartan. Amlodipine<br />dosage recommendations have not been established in patients with mild to moderate hepatic&nbsp;impairment. When switching eligible hypertensive patients (see section 4.1) with hepatic impairment<br />to amlodipine or Amlodipine/Valsartan tablets, the lowest available dose of amlodipine monotherapy<br />or of the amlodipine component, respectively, should be used.<br />Elderly (age 65 years or over)<br />In elderly patients, caution is required when increasing the dosage. When switching eligible elderly<br />hypertensive patients (see section 4.1) to amlodipine or Amlodipine/Valsartan tablets, the lowest<br />available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be<br />used.<br />Paediatric population<br />The safety and efficacy of Amlodipine/Valsartan tablets in children aged below 18 years have not been<br />established. No data are available.<br />Method of administration<br />Oral use.<br />It is recommended to take Amlodipine/Valsartan tablets with some water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substances, or to any of the excipients listed in section 6.1.
• Severe hepatic impairment, biliary cirrhosis or cholestasis.
• Concomitant use of Amlodipine/Valsartan tablets with aliskiren-containing products in patients with
diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
• Severe hypotension.
• Shock (including cardiogenic shock).
• Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy
and high grade aortic stenosis).
• Haemodynamically unstable heart failure after acute myocardial infarction.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of amlodipine in hypertensive crisis have not been established.<br />Pregnancy<br />Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless<br />continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in pregnancy.</p><p>When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if<br />appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />Sodium- and/or volume-depleted patients<br />Excessive hypotension was seen in 0.4% of patients with uncomplicated hypertension treated with<br />Amlodipine/Valsartan tablets in placebo-controlled studies. In patients with an activated reninangiotensin<br />system (such as volume- and/or salt-depleted patients receiving high doses of diuretics)<br />who are receiving angiotensin receptor blockers, symptomatic hypotension may occur. Correction of<br />this condition prior to administration of Amlodipine/Valsartan tablets or close medical supervision at<br />the start of treatment is recommended.<br />If hypotension occurs with Amlodipine/Valsartan tablets, the patient should be placed in the supine<br />position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued<br />once blood pressure has been stabilised.<br />Hyperkalaemia<br />Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing<br />potassium, or other medicinal products that may increase potassium levels (heparin, etc.) should be<br />undertaken with caution and with frequent monitoring of potassium levels.<br />Renal artery stenosis<br />Amlodipine/Valsartan tablets should be used with caution to treat hypertension in patients with<br />unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum<br />creatinine may increase in such patients.<br />Kidney transplantation<br />To date there is no experience of the safe use of Amlodipine/Valsartan tablets in patients who have had<br />a recent kidney transplantation.<br />Hepatic impairment<br />Valsartan is mostly eliminated unchanged via the bile. The half life of amlodipine is prolonged and<br />AUC values are higher in patients with impaired liver function; dosage recommendations have not<br />been established. Particular caution should be exercised when administering Amlodipine/Valsartan<br />tablets to patients with mild to moderate hepatic impairment or biliary obstructive disorders.<br />In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended<br />dose is 80 mg valsartan.<br />Renal impairment<br />No dosage adjustment of Amlodipine/Valsartan tablets is required for patients with mild to moderate<br />renal impairment (GFR &gt;30 ml/min/1.73 m2). Monitoring of potassium levels and creatinine is advised<br />in moderate renal impairment.</p><p>Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist<br />valsartan as their renin-angiotensin system is affected by the primary disease.<br />Angioedema<br />Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling<br />of the face, lips, pharynx and/or tongue, has been reported in patients treated with valsartan. Some of<br />these patients previously experienced angioedema with other medicinal products, including ACE<br />inhibitors. Amlodipine/Valsartan tablets should be discontinued immediately in patients who develop<br />angioedema and should not be re-administered.<br />Heart failure/post-myocardial infarction<br />As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal<br />function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal<br />function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE<br />inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive<br />azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with<br />valsartan. Evaluation of patients with heart failure or post-myocardial infarction should always include<br />assessment of renal function.<br />In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New<br />York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine<br />was associated with increased reports of pulmonary oedema despite no significant difference in the<br />incidence of worsening heart failure as compared to placebo.<br />Calcium channel blockers, including amlodipine, should be used with caution in patients with<br />congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.<br />Aortic and mitral valve stenosis<br />As with all other vasodilators, special caution is indicated in patients suffering from mitral stenosis or<br />significant aortic stenosis that is not high grade.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of<br />hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual<br />blockade of RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is therefore not<br />recommended (see sections 4.5 and 5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist<br />supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.<br />ACE inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy.</p><p>Amlodipine/Valsartan tablets has not been studied in any patient population other than hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions common to the combination<br />No drug-drug interaction studies have been performed with Amlodipine/Valsartan tablets and other<br />medicinal products.<br />To be taken into account with concomitant use<br />Other antihypertensive agents<br />Commonly used antihypertensive agents (e.g. alpha blockers, diuretics) and other medicinal products<br />which may cause hypotensive adverse effects (e.g. tricyclic antidepressants, alpha blockers for<br />treatment of benign prostate hyperplasia) may increase the antihypertensive effect of the combination.<br />Interactions linked to amlodipine<br />Concomitant use not recommended<br />Grapefruit or grapefruit juice<br />Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability<br />may be increased in some patients, resulting in increased blood pressure lowering effects.<br />Caution required with concomitant use<br />CYP3A4 inhibitors<br />Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole<br />antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to<br />significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic<br />variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus<br />be required.<br />CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin,<br />fosphenytoin, primidone], rifampicin, Hypericum perforatum)<br />Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine<br />may vary. Therefore, blood pressure should be monitored and dose regulation considered both during<br />and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin,<br />hypericum perforatum).<br />Simvastatin<br />Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77%<br />increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose<br />of simvastatin to 20 mg daily in patients on amlodipine.</p><p>Dantrolene (infusion)<br />In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with<br />hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of<br />hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as<br />amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of<br />malignant hyperthermia.<br />To be taken into account with concomitant use<br />Others<br />In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin,<br />warfarin or ciclosporin.<br />Interactions linked to valsartan<br />Concomitant use not recommended<br />Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II<br />receptor antagonists, including valsartan. Therefore, careful monitoring of serum lithium levels is<br />recommended during concomitant use. If a diurectic is also used, the risk of lithium toxicity may<br />presumably be increased further with Amlodipine/Valsartan tablets.<br />Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other<br />substances that may increase potassium levels<br />If a medicinal product that affects potassium levels is to be prescribed in combination with valsartan,<br />monitoring of potassium plasma levels is advised.<br />Caution required with concomitant use<br />Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors,<br />acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs<br />When angiotensin II antagonists are administered simultaneously with NSAIDs attenuation of the<br />antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and<br />NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum<br />potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended,<br />as well as adequate hydration of the patient.<br />Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)<br />The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the<br />hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of&nbsp;inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may<br />increase the systemic exposure to valsartan.<br />Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren<br />Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE<br />inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as<br />hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to<br />the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<br />Others<br />In monotherapy with valsartan, no interactions of clinical significance have been found with the<br />following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin,<br />hydrochlorothiazide, amlodipine, glibenclamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Amlodipine<br />The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive<br />toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when<br />there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.<br />Valsartan<br />The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of<br />pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of<br />pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors<br />during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot<br />be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II<br />Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued<br />AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative<br />antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate,<br />alternative therapy should be started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human<br />foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal<br />toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check<br />of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections<br />4.3 and 4.4).<br />Breast-feeding<br />Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has<br />been estimated with an interquartile range of 3&ndash;7%, with a maximum of 15%. The effect of amlodipine<br />on infants is unknown. No information is available regarding the use of Amlodipine/Valsartan tablets<br />during breast-feeding, therefore Amlodipine/Valsartan tablets is not recommended and alternative<br />treatments with better established safety profiles during breast-feeding are preferable, especially while<br />nursing a newborn or preterm infant.<br />Fertility<br />There are no clinical studies on fertility with Amlodipine/Valsartan tablets.<br />Valsartan<br />Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses<br />up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis<br />(calculations assume an oral dose of 320 mg/day and a 60-kg patient).<br />Amlodipine<br />Reversible biochemical changes in the head of spermatozoa have been reported in some patients<br />treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of<br />amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients taking Amlodipine/Valsartan tablets and driving vehicles or using machines should take into<br />account that dizziness or weariness may occasionally occur.<br />Amlodipine can have mild or moderate influence on the ability to drive and use machines. If patients<br />taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be<br />impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The safety of Amlodipine/Valsartan tablets has been evaluated in five controlled clinical studies with<br />5,175 patients, 2,613 of whom received valsartan in combination with amlodipine. The following<br />adverse reactions were found to be the most frequently occurring or the most significant or severe:<br />nasopharyngitis, influenza, hypersensitivity, headache, syncope, orthostatic hypotension, oedema,<br />pitting oedema, facial oedema, oedema peripheral, fatigue, flushing, asthenia and hot flush.<br />Tabulated list of adverse reactions</p><p>Adverse reactions have been ranked under headings of frequency using the following convention: very<br />common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to<br />&lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="2"><p><strong>MedDRA System organ class</strong></p></td><td colspan="" rowspan="2"><p><strong>Adverse reactions</strong></p></td><td colspan="3" rowspan=""><p><strong>Frequency</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Exforge</strong></p></td><td colspan="" rowspan=""><p><strong>Amlodipine</strong></p></td><td colspan="" rowspan=""><p><strong>Valsartan</strong></p></td></tr><tr><td colspan="" rowspan="2"><p>Infections and infestations</p></td><td colspan="" rowspan=""><p>Nasopharyngitis</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Influenza</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="4"><p>Blood and lymphatic system disorders</p></td><td colspan="" rowspan=""><p>Haemoglobin and haematocrit decreased</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Leukopenia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Neutropenia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Thrombocytopenia, sometimes with purpura</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Immune system disorders</p></td><td colspan="" rowspan=""><p>Hypersensitivity</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan="7"><p>Metabolism and nutrition disorders</p></td><td colspan="" rowspan=""><p>Anorexia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hypercalcaemia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperglycaemia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperlipidaemia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperuricaemia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hypokalaemia</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hyponatraemia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="5"><p>Psychiatric disorders</p></td><td colspan="" rowspan=""><p>Depression</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Anxiety</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Insomnia/sleep disorders</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Mood swings</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Confusion</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="13"><p>Nervous system disorders</p></td><td colspan="" rowspan=""><p>Coordination abnormal</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Dizziness</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Dizziness postural</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Dysgeusia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Extrapyramidal syndrome</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Headache</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hypertonia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Paraesthesia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Peripheral neuropathy, neuropathy</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Somnolence</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Syncope</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Tremor</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hypoesthesia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="2"><p>Eye disorders</p></td><td colspan="" rowspan=""><p>Visual disturbance</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Visual impairment</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="2"><p>Ear and labyrinth disorders</p></td><td colspan="" rowspan=""><p>Tinnitus</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Vertigo</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan="5"><p>Cardiac disorders</p></td><td colspan="" rowspan=""><p>Palpitations</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Syncope</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Tachycardia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Myocardial infarction</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="4"><p>Vascular disorders</p></td><td colspan="" rowspan=""><p>Flushing</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hypotension</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Orthostatic hypotension</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Vasculitis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan="4"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="" rowspan=""><p>Cough</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Dyspnoea</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Pharyngolaryngeal pain</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Rhinitis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="11"><p>Gastrointestinal disorders</p></td><td colspan="" rowspan=""><p>Abdominal discomfort, abdominal pain upper</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Change of bowel habit</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Constipation</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Diarrhoea</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Dry mouth</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Dyspepsia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Gastritis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Gingival hyperplasia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Nausea</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Pancreatitis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Vomiting</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="3"><p>Hepatobiliary disorders</p></td><td colspan="" rowspan=""><p>Liver function test abnormal, including blood bilirubin increase</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare*</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Hepatitis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Intrahepatic cholestasis, jaundice</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="17"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="" rowspan=""><p>Alopecia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Angioedema</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Dermatitis bullous</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Erythema</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Erythema multiforme</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Exanthema</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Hyperhidrosis</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Photosensitivity reaction</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Pruritus</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Purpura</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Rash</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Skin discolouration</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Urticaria and other forms of rash</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Exfoliative dermatitis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Stevens-Johnson syndrome</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Quincke oedema</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Very rare</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Toxic Epidermal Necrolysis</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="7"><p>Musculoskeletal and connective tissue disorders</p></td><td colspan="" rowspan=""><p>Arthralgia</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Back pain</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Joint swelling</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Muscle spasm</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Myalgia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Ankle swelling</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Sensation of heaviness</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="6"><p>Renal and urinary disorders</p></td><td colspan="" rowspan=""><p>Blood creatinine increased</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Micturition disorder</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Nocturia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Pollakiuria</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Polyuria</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Renal failure and impairment</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan="3"><p>Reproductive system and breast disorders</p></td><td colspan="" rowspan=""><p>Impotence</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Erectile dysfunction</p></td><td colspan="" rowspan=""><p>Rare</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Gynaecomastia</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="10"><p>General disorders and administration site conditions</p></td><td colspan="" rowspan=""><p>Asthenia</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Discomfort, malaise</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Fatigue</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Uncommon</p></td></tr><tr><td colspan="" rowspan=""><p>Facial oedema</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Flushing, hot flush</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Non cardiac chest pain</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Oedema</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Oedema peripheral</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Pain</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Pitting oedema</p></td><td colspan="" rowspan=""><p>Common</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan="3"><p>Investigations</p></td><td colspan="" rowspan=""><p>Blood potassium increased</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Not known</p></td></tr><tr><td colspan="" rowspan=""><p>Weight increase</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr><tr><td colspan="" rowspan=""><p>Weight decrease</p></td><td colspan="" rowspan=""><p>--</p></td><td colspan="" rowspan=""><p>Uncommon</p></td><td colspan="" rowspan=""><p>--</p></td></tr></tbody></table><p>* Mostly consistent with cholestasis</p><p><u>Additional information on the combination</u></p><p>Peripheral oedema, a recognised side effect of amlodipine, was generally observed at a lower incidence in patients who received the amlodipine/valsartan combination than in those who received amlodipine alone. In double-blind, controlled clinical trials, the incidence of peripheral oedema by dose was as follows:</p><p>&nbsp;</p><p>&nbsp;</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="2" rowspan="2" style="vertical-align:middle"><p>% of patients who experienced peripheral oedema</p></td><td colspan="5" rowspan="" style="vertical-align:middle"><p><strong>Valsartan (mg)</strong></p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>0</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>40</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>80</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>160</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>320</p></td></tr><tr><td colspan="" rowspan="4" style="vertical-align:middle"><p><strong>Amlodipine (mg)</strong></p><p>&nbsp;</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>3.0</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>5.5</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2.4</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>1.6</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.9</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>2.5</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>8.0</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2.3</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>5.4</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2.4</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>3.9</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>5</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>3.1</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>4.8</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2.3</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2.1</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2.4</p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p>10</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>10.3</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>NA</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>NA</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>9.0</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>9.5</p></td></tr></tbody></table><p>The mean incidence of peripheral oedema evenly weighted across all doses was 5.1% with the amlodipine/valsartan combination.</p><p><u>Additional information on the individual components</u></p><p>Adverse reactions previously reported with one of the individual components (amlodipine or valsartan) may be potential adverse reactions with Exforge as well, even if not observed in clinical trials or during the post-marketing period.</p><p><em><u>Amlodipine</u></em></p><p>&nbsp;</p><p>&nbsp;</p><table cellspacing="0" cellpadding="2" border="0" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><em>Common</em></p></td><td colspan="" rowspan=""><p>Somnolence, dizziness, palpitations, abdominal pain, nausea, ankle swelling.</p></td></tr><tr><td colspan="" rowspan=""><p><em>Uncommon</em></p></td><td colspan="" rowspan=""><p>Insomnia, mood changes (including anxiety), depression, tremor, dysgeusia, syncope, hypoesthesia, visual disturbance (including diplopia), tinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder, increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease.</p></td></tr><tr><td colspan="" rowspan=""><p><em>Rare</em></p></td><td colspan="" rowspan=""><p>Confusion.</p></td></tr><tr><td colspan="" rowspan=""><p><em>Very rare</em></p></td><td colspan="" rowspan=""><p>Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation), vasculitis, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity.</p></td></tr><tr><td colspan="" rowspan=""><p><em>Not known</em></p></td><td colspan="" rowspan=""><p>Toxic Epidermal Necrolysis</p></td></tr></tbody></table><p>* mostly consistent with cholestasis</p><p>Exceptional cases of extrapyramidal syndrome have been reported.</p><p><em><u>Valsartan</u></em></p><table cellspacing="0" cellpadding="2" border="0" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><em>Not known</em></p></td><td colspan="" rowspan=""><p>Decrease in haemoglobin, decrease in haematocrit, neutropenia, thrombocytopenia, increase of serum potassium, elevation of liver function values including increase of serum bilirubin, renal failure and impairment, elevation of serum creatinine, angioedema, myalgia, vasculitis, hypersensitivity including serum sickness.</p></td></tr></tbody></table><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2340.<br />Toll free phone: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />There is no experience of overdose with Amlodipine/Valsartan tablets. The major symptom of<br />overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine<br />may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and<br />potentially prolonged systemic hypotension up to and including shock with fatal outcome have been<br />reported.<br />Treatment<br />If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of<br />activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine<br />has been shown to significantly decrease amlodipine absorption. Clinically significant hypotension due<br />to Amlodipine/Valsartan tablets overdose calls for active cardiovascular support, including frequent<br />monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating<br />fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood<br />pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be<br />beneficial in reversing the effects of calcium channel blockade.<br />Both valsartan and amlodipine are unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II antagonists,<br />combinations; angiotensin II antagonists and calcium channel blockers, ATC code: C09DB01</p><p>Amlodipine/Valsartan tablets combines two antihypertensive compounds with complementary<br />mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to<br />the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. The<br />combination of these substances has an additive antihypertensive effect, reducing blood pressure to a<br />greater degree than either component alone.<br />Amlodipine/Valsartan<br />The combination of amlodipine and valsartan produces dose-related additive reduction in blood<br />pressure across its therapeutic dose range. The antihypertensive effect of a single dose of the<br />combination persisted for 24 hours.<br />Placebo-controlled trials<br />Over 1,400 hypertensive patients received Amlodipine/Valsartan tablets once daily in two placebocontrolled<br />trials. Adults with mild to moderate uncomplicated essential hypertension (mean sitting<br />diastolic blood pressure &ge;95 and &lt;110 mmHg) were enrolled. Patients with high cardiovascular risks &ndash;<br />heart failure, type I and poorly controlled type II diabetes and history of myocardial infarction or<br />stroke within one year &ndash; were excluded.<br />Active-controlled trials in patients who were non-responders to monotherapy<br />A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation<br />of blood pressure (trough sitting diastolic blood pressure &lt;90 mmHg at the end of the trial) in patients<br />not adequately controlled on valsartan 160 mg in 75% of patients treated with amlodipine/valsartan 10<br />mg/160 mg and 62% of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53% of<br />patients remaining on valsartan 160 mg. The addition of amlodipine 10 mg and 5 mg produced an<br />additional reduction in systolic/diastolic blood pressure of 6.0/4.8 mmHg and 3.9/2.9 mmHg,<br />respectively, compared to patients who remained on valsartan 160 mg only.<br />A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation<br />of blood pressure (trough sitting diastolic blood pressure &lt;90 mmHg at the end of the trial) in patients<br />not adequately controlled on amlodipine 10 mg in 78% of patients treated with amlodipine/valsartan<br />10 mg/160 mg, compared to 67% of patients remaining on amlodipine 10 mg. The addition of<br />valsartan 160 mg produced an additional reduction in systolic/diastolic blood pressure of 2.9/2.1<br />mmHg compared to patients who remained on amlodipine 10 mg only.<br />Amlodipine/Valsartan tablets was also studied in an active-controlled study of 130 hypertensive<br />patients with mean sitting diastolic blood pressure &ge;110 mmHg and &lt;120 mmHg. In this study<br />(baseline blood pressure 171/113 mmHg), an Amlodipine/Valsartan tablets regimen of 5 mg/160 mg<br />titrated to 10 mg/160 mg reduced sitting blood pressure by 36/29 mmHg as compared to 32/28 mmHg<br />with a regimen of lisinopril/hydrochlorothiazide 10 mg/12.5 mg titrated to 20 mg/12.5 mg.</p><p>In two long-term follow-up studies the effect of Amlodipine/Valsartan tablets was maintained for over<br />one year. Abrupt withdrawal of Amlodipine/Valsartan tablets has not been associated with a rapid<br />increase in blood pressure.<br />Age, gender, race or body mass index (&ge;30 kg/m2, &lt;30 kg/m2) did not influence the response to<br />Amlodipine/Valsartan tablets.<br />Amlodipine/Valsartan tablets has not been studied in any patient population other than hypertension.<br />Valsartan has been studied in patients with post myocardial infarction and heart failure. Amlodipine<br />has been studied in patients with chronic stable angina, vasospastic angina and angiographically<br />documented coronary artery disease.<br />Amlodipine<br />The amlodipine component of Amlodipine/Valsartan tablets inhibits the transmembrane entry of<br />calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action<br />of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in<br />peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds<br />to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac<br />muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions<br />into these cells through specific ion channels.<br />Following administration of therapeutic doses to patients with hypertension, amlodipine produces<br />vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood<br />pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with<br />chronic dosing.<br />Plasma concentrations correlate with effect in both young and elderly patients.<br />In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a<br />decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal<br />plasma flow, without change in filtration fraction or proteinuria.<br />As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and<br />during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have<br />generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on<br />left ventricular end diastolic pressure or volume. In haemodynamic studies, amlodipine has not been<br />associated with a negative inotropic effect when administered in the therapeutic dose range to intact<br />animals and humans, even when co-administered with beta blockers to humans.<br />Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals<br />or humans. In clinical studies in which amlodipine was administered in combination with beta blockers<br />to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters<br />were observed.</p><p>Use in patients with hypertension<br />A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering<br />treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies:<br />amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE-inhibitor) as<br />first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate<br />hypertension.<br />A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of<br />4.9 years. The patients had at least one additional coronary heart disease risk factor, including:<br />previous myocardial infarction or stroke (&gt;6 months prior to enrollment) or documentation of other<br />atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density<br />lipoprotein - cholesterol &lt;35 mg/dl or &lt;0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed<br />by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).<br />The primary endpoint was a composite of fatal coronary heart disease or non-fatal myocardial<br />infarction. There was no significant difference in the primary endpoint between amlodipine-based<br />therapy and chlorthalidone-based therapy: risk ratio (RR) 0.98 95% CI (0.90-1.07) p=0.65. Among<br />secondary endpoints, the incidence of heart failure (component of a composite combined<br />cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the<br />chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was<br />no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidonebased<br />therapy RR 0.96 95% CI [0.89-1.02] p=0.20.<br />Valsartan<br />Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively<br />on the receptor subtype AT1, which is responsible for the known actions of angiotensin II. The<br />increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may<br />stimulate the unblocked receptor subtype AT2, which appears to counterbalance the effect of the<br />AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much<br />(about 20,000-fold) greater affinity for the AT1 receptor than for the AT2 receptor.<br />Valsartan does not inhibit ACE, also known as kininase II, which converts angiotensin I to angiotensin<br />II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or<br />substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials<br />where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (p<br />&lt;0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6%<br />versus 7.9%, respectively). In a clinical trial of patients with a history of dry cough during ACE<br />inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide<br />diuretic experienced coughing, compared to 68.5% of those treated with an ACE inhibitor (p &lt;0.05).<br />Valsartan does not bind to or block other hormone receptors or ion channels known to be important in<br />cardiovascular regulation.</p><p>Administration of valsartan to patients with hypertension results in a drop in blood pressure without<br />affecting pulse rate.<br />In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs<br />within 2 hours, and the peak drop in blood pressure is achieved within 4&ndash;6 hours. The antihypertensive<br />effect persists over 24 hours after administration. During repeated administration, the maximum<br />reduction in blood pressure with any dose is generally attained within 2&ndash;4 weeks and is sustained<br />during long-term therapy. Abrupt withdrawal of valsartan has not been associated with rebound<br />hypertension or other adverse clinical events.<br />Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs<br />Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an<br />ARB.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular<br />disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D<br />was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and<br />mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as<br />compared to monotherapy was observed. Given their similar pharmacodynamic properties, these<br />results are also relevant for other ACE inhibitors and ARBs.<br />ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic<br />nephropathy (see section 4.4).<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)<br />was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or<br />an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or<br />both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular<br />death and stroke were both numerically more frequent in the aliskiren group than in the placebo group<br />and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal<br />dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Linearity<br />Amlodipine and valsartan exhibit linear pharmacokinetics.<br />Amlodipine/Valsartan<br />Following oral administration of Amlodipine/Valsartan tablets, peak plasma concentrations of<br />valsartan and amlodipine are reached in 3 and 6&ndash;8 hours, respectively. The rate and extent of&nbsp;absorption of Amlodipine/Valsartan tablets are equivalent to the bioavailability of valsartan and<br />amlodipine when administered as individual tablets.<br />Amlodipine<br />Absorption: After oral administration of therapeutic doses of amlodipine alone, peak plasma<br />concentrations of amlodipine are reached in 6&ndash;12 hours. Absolute bioavailability has been calculated<br />as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.<br />Distribution: Volume of distribution is approximately 21 l/kg. In vitro studies with amlodipine have<br />shown that approximately 97.5% of circulating drug is bound to plasma proteins.<br />Biotransformation: Amlodipine is extensively (approximately 90%) metabolised in the liver to<br />inactive metabolites.<br />Elimination: Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of<br />approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration<br />for 7&ndash;8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in<br />urine.<br />Valsartan<br />Absorption: Following oral administration of valsartan alone, peak plasma concentrations of valsartan<br />are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured<br />by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although<br />from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups.<br />This reduction in AUC is not, however, accompanied by a clinically significant reduction in the<br />therapeutic effect, and valsartan can therefore be given either with or without food.<br />Distribution: The steady-state volume of distribution of valsartan after intravenous administration is<br />about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly<br />bound to serum proteins (94&ndash;97%), mainly serum albumin.<br />Biotransformation: Valsartan is not transformed to a high extent as only about 20% of dose is<br />recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations<br />(less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.<br />Elimination: Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is<br />primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as<br />unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h<br />and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.<br />Special populations<br />Paediatric population (age below 18 years)<br />No pharmacokinetic data are available in the paediatric population.</p><p>Elderly (age 65 years or over)<br />Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly<br />patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC)<br />and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the<br />young, therefore caution is required when increasing the dosage.<br />Renal impairment<br />The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected<br />for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation<br />was seen between renal function and systemic exposure to valsartan.<br />Hepatic impairment<br />Very limited clinical data are available regarding amlodipine administration in patients with hepatic<br />impairment. Patients with hepatic impairment have decreased clearance of amlodipine with resulting<br />increase of approximately 40&ndash;60% in AUC. On average, in patients with mild to moderate chronic<br />liver disease exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers<br />(matched by age, sex and weight). Caution should be exercised in patients with liver disease (see<br />section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amlodipine/Valsartan<br />Adverse reactions observed in animal studies with possible clinical relevance were as follows:<br />Histopathological signs of inflammation of the glandular stomach was seen in male rats at an exposure<br />of about 1.9 (valsartan) and 2.6 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg<br />amlodipine. At higher exposures, there were ulceration and erosion of the stomach mucosa in both<br />females and males. Similar changes were also seen in the valsartan alone group (exposure 8.5&ndash;11.0<br />times the clinical dose of 160 mg valsartan).<br />An increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as<br />well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an<br />exposure of 8&ndash;13 (valsartan) and 7&ndash;8 (amlodipine) times the clinical doses of 160 mg valsartan and 10<br />mg amlodipine. Similar changes were found in the valsartan alone group (exposure 8.5&ndash;11.0 times the<br />clinical dose of 160 mg valsartan).<br />In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed<br />sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12 (valsartan) and 10<br />(amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine. Dilated ureters were<br />also found in the valsartan alone group (exposure 12 times the clinical dose of 160 mg valsartan).<br />There were only modest signs of maternal toxicity (moderate reduction of body weight) in this study.</p><p>The no-observed-effect-level for developmental effects was observed at 3- (valsartan) and 4-<br />(amlodipine) fold the clinical exposure (based on AUC).<br />For the single compounds there was no evidence of mutagenicity, clastogenicity or carcinogenicity.<br />Amlodipine<br />Reproductive toxicology<br />Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of<br />labour and decreased pup survival at dosages approximately 50 times greater than the maximum<br />recommended dosage for humans based on mg/kg.<br />Impairment of fertility<br />There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14<br />days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose<br />of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine<br />besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma<br />follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in<br />the number of mature spermatids and Sertoli cells.<br />Carcinogenesis, mutagenesis<br />Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide<br />daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The<br />highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10<br />mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.<br />Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.<br />* Based on patient weight of 50 kg<br />Valsartan<br />Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction<br />and development.<br />In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to<br />lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening)<br />in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the<br />maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320<br />mg/day and a 60-kg patient).<br />In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a<br />reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of<br />changes in renal haemodynamics (slightly raised blood urea nitrogen, and renal tubular hyperplasia&nbsp;and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18<br />times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of<br />320 mg/day and a 60-kg patient).<br />In marmosets at comparable doses, the changes were similar though more severe, particularly in the<br />kidney where the changes developed to a nephropathy including raised blood urea nitrogen and<br />creatinine.<br />Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were<br />considered to be caused by the pharmacological action of valsartan which produces prolonged<br />hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy<br />of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose PH101<br />&bull; Microcrystalline Cellulose PH102<br />&bull; Crospovidone<br />&bull; Colloidal Silicon Dioxide<br />&bull; Magnesium Stearate<br />&bull; Opadry Yellow 03F220064<br />&bull; Polyethylene Glycol 6000 P<br />&bull; Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.the original package, in order to protect from moisture</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10/320mg are available in a box of 4 blisters, 7 tablets per each blister.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov -2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>